The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•1 May 2026•

1 min read

Gossamer Bio Faces Class Action Lawsuit After 80% Stock Crash on Trial Failure

Key Facts

1A securities class action lawsuit was filed against Gossamer Bio following the failure of its Phase 3 PROSERA study to meet its primary endpoint.

2The company announced on February 23, 2026, that top-line results for its Phase 3 PROSERA study did not meet the primary endpoint of change in six-minute-walk distance.

Gossamer Bio is facing a securities class action lawsuit following the failure of its Phase 3 PROSERA study to meet its primary endpoint. On February 23, 2026, the company revealed that top-line results did not achieve the required change in the six-minute-walk distance metric. This announcement triggered a massive 80% collapse in GOSS shares, wiping out a significant portion of the company's market value. The lawsuit alleges that investors were misled regarding the drug's potential between June 2025 and February 2026. This legal challenge adds significant pressure to the biotech firm as it grapples with the clinical failure. Analysts are closely monitoring the fallout as the company navigates both regulatory hurdles and investor litigation.